ArticleAntimicrobial agents and chemotherapy2009
Tuberculosis and trimethoprim-sulfamethoxazole.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01832987 (Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis
Who cites it
39 citing papers in PubMed, 104 citations in OpenAlex.
- Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.BMC medicine · 2016Trial
- A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.The New England journal of medicine · 2014Trial
- COVID-19-associated opportunistic infections: a snapshot on the current reports.Clinical and experimental medicine · 2022Review
- The Pup-Proteasome System Protects Mycobacteria from Antimicrobial Antifolates.Antimicrobial agents and chemotherapy · 2021Article
- Potential antibacterial and antifungal activities of novel sulfamidophosphonate derivatives bearing the quinoline or quinolone moiety.Archiv der Pharmazie · 2021Article
- Mutations of folC cause increased susceptibility to sulfamethoxazole in Mycobacterium tuberculosis.Scientific reports · 2021Article
- Repurposing Immunomodulatory Drugs to Combat Tuberculosis.Frontiers in immunology · 2021Review
- Metal-Peptide Complexes as Promising Antibiotics to Fight Emerging Drug Resistance: New Perspectives in Tuberculosis.Antibiotics (Basel, Switzerland) · 2020Review
- SubstitutedMolecules (Basel, Switzerland) · 2019Article
- Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV.Journal of the International AIDS Society · 2019Observational
- Incidence of tuberculosis in children on antiretroviral therapy: a retrospective cohort study.BMC research notes · 2018Article
- Synthesis of 2,4-Diaminopyrimidine Core-Based Derivatives and Biological Evaluation of Their Anti-Tubercular Activities.Molecules (Basel, Switzerland) · 2017Article
- Bacterial infection imaging with [Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.The Journal of antimicrobial chemotherapy · 2017Article
- Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform.Nature microbiology · 2017Article
- Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.Antimicrobial agents and chemotherapy · 2016Article
- Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.Antimicrobial agents and chemotherapy · 2015Article
- Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance.Antimicrobial agents and chemotherapy · 2015Review
- New insights into TB physiology suggest untapped therapeutic opportunities.Immunological reviews · 2015Review
- Tuberculosis treatment and drug regimens.Cold Spring Harbor perspectives in medicine · 2015Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sulfonamides were the first drugs with antituberculous effects. Their use was abandoned and basically forgotten with the advent of streptomycin and isoniazid combination treatment. There is a widespread belief, apparently based on testing a single isolate on questionable media, that Mycobacterium tuberculosis is resistant to trimethoprim-sulfamethoxazole (TMP-SMX). We saw a complex immunocompromised patient with tuberculosis who was initially treated with TMP-SMX without antituberculous drugs and defervesced on this treatment. An isolate of M. tuberculosis from this patient was found to be sensitive to TMP-SMX. We examined how frequently M. tuberculosis is sensitive to TMP-SMX. Isolates were tested for susceptibility to TMP-SMX on supplemented Middlebrook 7H10 plates. We found that 43 of 44 (98%) isolates of M. tuberculosis were susceptible to the combination of < or = 1 microg/ml of TMP and 19 microg/ml of SMX (< or = 1/19 microg/ml). Thus, the vast majority of our M. tuberculosis isolates were susceptible to TMP-SMX at an MIC similar to that for Mycobacterium kansasii, Mycobacterium marinum, and sensitive rapidly growing mycobacteria, organisms successfully treated with TMP-SMX as part of the treatment regimen. It is possible that TMP-SMX may be useful in treating patients with multiple-drug-resistant and extended drug-resistant tuberculosis. We feel that a clinical trial looking at the effectiveness of TMP-SMX as an antituberculous drug is worthwhile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.